Potaba® (Potassium para-aminobenzoate)

Capsules: White/white gelatin capsule shell containing the active ingredient 500mg of potassium para-aminobenzoate powder.

Capsules: White/white size zero gelatin capsules containing 500mg potassium para-aminobenzoate with 'Potaba 51' on the shell.

Peyronie's Disease

Scleroderma

Potaba capsules should be taken orally;six capsules four times daily with food.

Children: not recommended.

Potaba should not be taken by patients taking sulphonamides as it will inactivate this medication.

Treatment with Potaba should be interrupted during periods of low food intake (eg, during fasting, anorexia, nausea). This is to avoid the possible development of hypoglycaemia.

Potaba treatment should be given cautiously to patients with renal impairment and treatment discontinued if a hypersensitivity reaction occurs.

Potaba should not be taken by patients on sulphonamides; Potaba may cause inactivation of this medication.

With the exception of sulphonamides, no interactions with other medicaments have been established.

No information is available on this, therefore it is not recommended.

There is no evidence that Potaba has any effect on ability to drive or use machines.

Treatment with Potaba should be interrupted during periods of low food intake (e.g. during fasting, anorexia, nausea). This is to avoid the possible development of hypoglycaemia. No serious adverse effects have been reported in patients treated with Potaba.

No particular problems are expected following overdosage with Potaba. Symptomatic and supportive therapy should be given as appropriate.

Para-aminobenzoate is considered a member of the Vitamin B complex. Small amounts are found in cereal, eggs, milk and meats. Detectable amounts are normally present in human blood, spinal fluid, urine and sweat. The pharmacological action of this chemical has not been clearly established, but it has been suggested that the antifibrosis activity of Potaba is brought about by the drug increasing oxygen uptake at the tissue level. Fibrosis is believed to occur from either too much serotonin or too little monoamine oxidase activity over a period of time. The activity of monoamine oxidase is dependant on an adequate oxygen supply. By increasing oxygen supply at tissue level Potaba enhances monoamine oxidase activity thereby preventing or bringing about regression of fibrosis.

Potaba is rapidly absorbed and metabolised as food. Excretion is through renal function.

Not applicable.

None.

Sulphonamides.

Three years from date of manufacture.

Store below 25°C.

White polypropylene tube with tamper-evident polyethylene cap. A filler may be inserted to reduce ullage. Containers of 240 x 500mg capsules.

None stated.

Glenwood GmbH Riedener Weg 23 82319 Starnberg Germany

PL 22824/0001

28 April 1981 / 18 March 1998

20/10/2010